Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Short term Debt: 2019-2025

Historic Short term Debt for Burning Rock Biotech (BNR) over the last 1 years, with Jun 2025 value amounting to $200,000.

  • Burning Rock Biotech's Short term Debt was N/A to $200,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $200,000, marking a year-over-year change of. This contributed to the annual value of $372,000 for FY2021, which is 93.00% down from last year.
  • As of Q2 2025, Burning Rock Biotech's Short term Debt stood at $200,000, which was down 46.24% from $372,000 recorded in Q4 2021.
  • In the past 5 years, Burning Rock Biotech's Short term Debt ranged from a high of $372,000 in Q4 2021 and a low of $200,000 during Q2 2025.
  • In the last 1 years, Burning Rock Biotech's Short term Debt had a median value of $200,000 in 2025 and averaged $200,000.
  • Data for Burning Rock Biotech's Short term Debt shows a maximum YoY plummeted of 93.00% (in 2021) over the last 5 years.
  • Burning Rock Biotech's Short term Debt (Quarterly) stood at $372,000 in 2021, then followed by $200,000 in 2025.
  • Its Short term Debt stands at $200,000 for Q2 2025, versus $372,000 for Q4 2021 and $5.3 million for Q4 2020.